@article{TP23465,
author = {Takashi Ishige},
title = {Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management},
journal = {Translational Pediatrics},
volume = {8},
number = {1},
year = {2019},
keywords = {},
abstract = {Impairment of growth is recognized as one of the most significant complications of inflammatory bowel disease (IBD) in pediatric patients. The reported incidence of growth failure at diagnosis is 15–40% in pediatric onset Crohn’s disease (CD) and 3–10% in ulcerative colitis (UC). Growth failure is associated with decreased appetite, abdominal symptoms, malabsorption due to mucosal inflammation, growth hormone (GH) resistance due to inflammation, and even genetic factors. Several population-based studies and cohort studies suggest that patients with pre-pubertal onset CD have a higher risk of growth failure at disease onset. Final adult height is still lower than that of healthy controls; however, its prevalence is generally lower than that at the disease onset. Several IBD treatments were reported to improve patients’ growth. In addition to enteral nutrition therapy, treatment with anti-tumor necrosis factor (TNF) agents was reported to have favorable effects on growth of patients with pre-pubertal onset CD. Avoiding corticosteroids (CS) and achieving deep remission seems to be important to maintain optimal growth in patients with pediatric onset IBD.},
issn = {2224-4344}, url = {https://tp.amegroups.org/article/view/23465}
}